IDEAYA Biosciences Inc
IDYA25.020USD
+0.520+2.12%
Close 07/28, 16:00（ET）Quotes delayed by 15 min
2.19BMarket Cap
LossP/E TTM
More Details of IDEAYA Biosciences Inc Company
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
Company Info
Ticker SymbolIDYA
Company nameIDEAYA Biosciences Inc
IPO dateMay 23, 2019
Founded at2015
CEOMr. Yujiro S. Hata
Number of employees131
Security typeOrdinary Share
Fiscal year-endMay 23
Address7000 Shoreline Ct, Suite 350
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94080
Phone16504436209
Websitehttps://www.ideayabio.com/
Ticker SymbolIDYA
IPO dateMay 23, 2019
Founded at2015
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
--
--
Dr. Michael A. White, Ph.D.
Dr. Michael A. White, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2024
FY2024Q4
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
By BusinessUSD
Name
Revenue
Proportion
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
By RegionUSD
Name
Revenue
Proportion
United States
7.00M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
Shareholding Stats
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.99%
BlackRock Institutional Trust Company, N.A.
8.17%
Janus Henderson Investors
7.31%
The Vanguard Group, Inc.
5.80%
Federated Hermes Global Investment Management Corp.
5.44%
Other
58.29%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.99%
BlackRock Institutional Trust Company, N.A.
8.17%
Janus Henderson Investors
7.31%
The Vanguard Group, Inc.
5.80%
Federated Hermes Global Investment Management Corp.
5.44%
Other
58.29%
Shareholder Types
Shareholders
Proportion
Investment Advisor
45.54%
Investment Advisor/Hedge Fund
33.49%
Hedge Fund
21.64%
Venture Capital
8.56%
Research Firm
4.37%
Individual Investor
0.91%
Pension Fund
0.77%
Sovereign Wealth Fund
0.59%
Bank and Trust
0.34%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
444
101.86M
116.30%
-6.31M
2025Q1
454
97.81M
111.68%
-11.15M
2024Q4
442
95.26M
108.96%
-7.87M
2024Q3
426
95.20M
112.79%
+2.56M
2024Q2
409
85.26M
112.59%
-3.91M
2024Q1
388
81.45M
108.91%
-1.44M
2023Q4
351
68.31M
105.94%
-512.62K
2023Q3
331
61.92M
105.66%
-3.64M
2023Q2
313
59.35M
103.37%
+5.88M
2023Q1
290
47.36M
97.90%
-6.95M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
13.13M
14.99%
+167.11K
+1.29%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.15M
8.17%
+286.75K
+4.18%
Mar 31, 2025
Janus Henderson Investors
6.40M
7.31%
+544.14K
+9.29%
Mar 31, 2025
The Vanguard Group, Inc.
5.08M
5.8%
+14.54K
+0.29%
Mar 31, 2025
Federated Hermes Global Investment Management Corp.
4.77M
5.44%
-295.60K
-5.84%
Mar 31, 2025
Point72 Asset Management, L.P.
4.41M
5.04%
+4.27M
+3048.93%
Jun 06, 2025
Logos Global Management LP
3.50M
4%
+500.00K
+16.67%
Mar 31, 2025
State Street Global Advisors (US)
3.45M
3.93%
+125.33K
+3.77%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.39M
3.87%
-395.42K
-10.45%
Mar 31, 2025
Deerfield Management Company, L.P.
3.27M
3.73%
+531.55K
+19.43%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
Tema Oncology ETF
1.99%
ALPS Medical Breakthroughs ETF
1.47%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
SPDR S&P Biotech ETF
0.61%
Direxion Daily S&P Biotech Bull 3X Shares
0.35%
ProShares Ultra Nasdaq Biotechnology
0.21%
Invesco Nasdaq Biotechnology ETF
0.19%
iShares Biotechnology ETF
0.17%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.12%
iShares Russell 2000 Growth ETF
0.12%
View more
Tema Oncology ETF
Proportion1.99%
ALPS Medical Breakthroughs ETF
Proportion1.47%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.88%
SPDR S&P Biotech ETF
Proportion0.61%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.35%
ProShares Ultra Nasdaq Biotechnology
Proportion0.21%
Invesco Nasdaq Biotechnology ETF
Proportion0.19%
iShares Biotechnology ETF
Proportion0.17%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proportion0.12%
iShares Russell 2000 Growth ETF
Proportion0.12%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
